Consistent with validation studies of women diagnosed with a first breast cancer conducted mainly in White populations, Predict accurately evaluated the 5-year breast cancer mortality for a diverse population of women diagnosed with a first estrogen receptor–positive cancer but overestimated mortality for women with a first estrogen receptor–negative cancer. This evidence concerns the gene ESR1 and cancer.